Current DEXA Screening Guidelines
All women aged 65 years and older should undergo DEXA screening for osteoporosis, and postmenopausal women younger than 65 years with elevated fracture risk (identified through clinical risk assessment tools) should also be screened. 1
Screening Recommendations by Population
Women
The 2025 USPSTF guideline establishes a clear age-based screening framework 1:
- Women ≥65 years: Universal DEXA screening recommended
- Postmenopausal women <65 years: Screen if elevated fracture risk identified through formal clinical risk assessment tools (e.g., FRAX)
- Two-step approach for younger postmenopausal women: First assess fracture risk using clinical tools, then proceed to DEXA if risk is elevated
The 2025 European guideline reinforces this approach, recommending DXA testing for younger adults with previous fracture or major risk factors such as chronic glucocorticoid use (≥5 mg prednisone equivalent daily for ≥3 months) 2.
Men
Men aged 70 years and older should be screened with DEXA 1. The American Academy of Family Physicians specifically recommends against screening men younger than 70 years without risk factors 1.
High-Risk Populations Requiring Earlier Screening
Regardless of age, DEXA is indicated for 2, 3:
- Prior fragility fracture (any low-trauma fracture in adulthood)
- Chronic glucocorticoid therapy (≥5 mg prednisone equivalent daily for ≥3 months)
- Diseases associated with bone loss: hyperparathyroidism, rheumatoid arthritis, chronic kidney disease
- Prostate cancer on androgen deprivation therapy (screen at 1-2 year intervals) 2
- Spinal cord injury with permanent motor/sensory dysfunction (scan total hip, proximal tibia, distal femur when medically stable) 2
- Height loss: Historical loss >4 cm (>1.5 inches) or prospective loss >2 cm (>0.8 inches) 2
Measurement Sites and Interpretation
DEXA should assess the lumbar spine and bilateral proximal femurs as the guideline-recommended standard 2. The WHO operational definition of osteoporosis is T-score ≤-2.5 at the femoral neck, though other measurement sites are interpreted analogously in clinical practice 4.
Special Populations
Transgender individuals: Calculate Z-scores using reference data matching gender identity. Screen based on hormone therapy compliance, gonadal removal status, and additional osteoporosis risk factors 2.
Common Pitfalls to Avoid
Don't rely on T-score alone: Bone density must be interpreted within the context of clinical risk factors—isolated BMD inadequately predicts actual fracture risk 4
Recognize site discordance: Different skeletal sites may show different T-scores; use the lowest value for diagnosis 5
Identify artifacts: Careful evaluation of graphical bands and artifact recognition is essential for accurate interpretation 5
Don't screen too young without risk factors: The American Academy of Family Physicians specifically recommends against screening women <65 years and men <70 years without identifiable risk factors 1
Vertebral Fracture Assessment (VFA)
Consider VFA or standard radiography when 2:
- T-score <-1.0 AND any of: women ≥70 years or men ≥80 years, historical height loss >4 cm, undocumented prior vertebral fracture, chronic glucocorticoid use
- T-score ≤-2.5 at spine or hip
- Acute onset back pain with osteoporosis risk factors
Follow-up Intervals
For patients on treatment: Reassess at minimum 12-month intervals to evaluate treatment effectiveness using least significant change methodology 2, 5. For high-risk populations like those with spinal cord injury or on androgen deprivation therapy, follow-up at 1-2 year intervals is recommended 2.